Celcuity (NASDAQ:CELC) Releases Quarterly Earnings Results, Misses Estimates By $0.28 EPS

Key Points

• Celcuity missed quarterly expectations: It reported a loss of $1.44 per share versus the $1.16 consensus estimate, while revenue of $0.09 million fell far short of the $4.42 million forecast.
• REVTORPYK received FDA approval and preferred Category 1 NCCN recommendations for certain advanced breast cancer patients. In the VIKTORIA-1 trial, gedatolisib-based treatment improved median progression-free survival and had fewer treatment discontinuations than a competing regimen.
• Celcuity expects commercial shipments to begin in late Q3 2026, supported by 88 oncology sales specialists and an estimated U.S. addressable market above $6 billion. However, its net loss widened to $78.9 million as launch expenses increased; the company ended June with $754 million in cash and investments and expects funding into 2029.

Celcuity (NASDAQ:CELC - Get Free Report) released its earnings results on Thursday. The company reported ($1.44) EPS for the quarter, missing analysts' consensus estimates of ($1.16) by ($0.28), Zacks reports. The company had revenue of $0.09 million during the quarter, compared to analysts' expectations of $4.42 million.

Here are the key takeaways from Celcuity's conference call:

• REVTORPYK was FDA-approved for HR-positive, HER2-negative advanced breast cancer without detected PIK3CA mutations, and both its doublet and triplet regimens received preferred Category 1 recommendations in the NCCN guidelines.
• In the PIK3CA-mutant VIKTORIA-1 cohort, gedatolisib-based regimens significantly improved median progression-free survival to approximately 11 months versus 5.6 months for alpelisib plus fulvestrant, while treatment discontinuation due to adverse events was lower for gedatolisib. Celcuity plans to submit an sNDA in the third quarter of 2026.
• Celcuity remains confident that commercial shipments will begin in late Q3 2026. The company has completed its commercial infrastructure, deployed 88 oncology sales specialists, begun an expanded-access program, and estimates a U.S. addressable market exceeding $6 billion annually.
• The VIKTORIA-2 first-line breast cancer program has been expanded to include endocrine-sensitive patients, potentially broadening gedatolisib’s use across most newly diagnosed advanced HR-positive, HER2-negative patients. Celcuity also expects to provide additional prostate cancer data in Q4 2026.
• Second-quarter net loss widened to $78.9 million from $45.3 million year over year, while selling, general and administrative expenses rose sharply due to launch preparation. The company ended June with $754 million in cash and investments and expects funding into 2029, helped by a $575 million convertible-note offering.

Celcuity Trading Up 6.2%

CELC stock traded up $5.40 during mid-day trading on Friday, hitting $92.00. 1,333,092 shares of the company were exchanged, compared to its average volume of 1,113,413. Celcuity has a 12-month low of $44.42 and a 12-month high of $151.02. The firm has a market capitalization of $4.49 billion, a P/E ratio of -23.59 and a beta of 0.20. The business has a fifty day simple moving average of $93.81 and a 200-day simple moving average of $108.56. The company has a quick ratio of 12.31, a current ratio of 12.31 and a debt-to-equity ratio of 6.04.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on CELC. Leerink Partners set a $155.00 price target on shares of Celcuity in a report on Tuesday, June 2nd. Citizens Jmp upped their price objective on shares of Celcuity from $160.00 to $177.00 and gave the stock a "market outperform" rating in a research report on Wednesday, July 15th. Wall Street Zen downgraded shares of Celcuity from a "hold" rating to a "sell" rating in a research report on Saturday, April 25th. Craig Hallum reissued a "buy" rating and set a $178.00 target price on shares of Celcuity in a research note on Wednesday, July 15th. Finally, Weiss Ratings upgraded Celcuity from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Thursday, June 4th. Ten research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $153.64.

Institutional Investors Weigh In On Celcuity

Several institutional investors and hedge funds have recently modified their holdings of the company. BNP Paribas Financial Markets boosted its stake in shares of Celcuity by 78.9% in the second quarter. BNP Paribas Financial Markets now owns 2,647 shares of the company's stock valued at $35,000 after purchasing an additional 1,167 shares during the period. US Bancorp DE boosted its position in Celcuity by 25.4% in the 3rd quarter. US Bancorp DE now owns 706 shares of the company's stock valued at $35,000 after buying an additional 143 shares during the period. Meeder Asset Management Inc. acquired a new position in shares of Celcuity in the fourth quarter worth $42,000. Tower Research Capital LLC TRC increased its position in shares of Celcuity by 211.2% during the second quarter. Tower Research Capital LLC TRC now owns 5,549 shares of the company's stock worth $74,000 after acquiring an additional 3,766 shares during the period. Finally, Kemnay Advisory Services Inc. acquired a new stake in shares of Celcuity in the fourth quarter valued at $101,000. Hedge funds and other institutional investors own 63.33% of the company's stock.

Celcuity News Roundup

Here are the key news stories impacting Celcuity this week:

• Positive Sentiment: HC Wainwright reaffirmed its Buy rating and maintained a $155 price target, implying substantial upside from recent trading levels. Benzinga analyst rating
• Positive Sentiment: Investor sentiment is being supported by the FDA approval of REVTORPYK and its rapid inclusion in the NCCN Category 1 guidelines. The treatment’s VIKTORIA-1 data showed strong efficacy and tolerability, potentially supporting rapid physician adoption and blockbuster commercial potential. Celcuity reportedly has approximately $754 million in cash, providing funding visibility through 2029 despite elevated launch spending. Celcuity REVTORPYK commercial story
• Neutral Sentiment: Stifel Nicolaus retained its Buy rating but reduced its price target to $150 from $175, while Needham maintained Buy and cut its target to $140 from $157. The reductions suggest analysts remain constructive on Celcuity’s long-term opportunity but are adjusting valuation assumptions after recent results and launch considerations. Stifel analyst rating Needham analyst rating
• Negative Sentiment: Second-quarter results showed a $1.44-per-share loss versus the $1.16 consensus estimate, while revenue of approximately $0.09 million was well below the $4.42 million expectation. Analysts subsequently reduced forecasts, highlighting near-term execution risk and the financial impact of commercial launch investments. Celcuity second-quarter 2026 results

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source